Abstract
Barrett’s oesophagus is a premalignant complication that occurs in approximately 10% of patients with gastro-oesophageal reflux disease (GORD). In patients with Barrett’s oesophagus, the risk of adenocarcinoma of the oesophagus approaches 0.5% per patient-years. Therefore, practice guidelines have been developed that suggest screening patients with GORD, particularly those with long-standing symptoms and those aged ≥50 years for the presence of Barrett’s metaplasia. These guidelines also suggest performing surveillance endoscopy for the development of dysplasia and/or cancer in patients found to harbour Barrett’s oesophagus at initial screening with the frequency of subsequent endoscopies dictated by the presence and grade of dysplasia. In patients with high-grade dysplasia and/or early adenocarcinoma, oesophagectomy is curative.
Given the important clinical and economic implications of GORD complicated by Barrett’s oesophagus, we review the costs associated with screening, surveillance and treatment for this condition. Although the majority of physicians recommend and/or perform surveillance for dysplasia in the setting of Barrett’s oesophagus, differences in endoscopic technique, surveillance intervals and cancer perception among practitioners influence total costs. In the US, it is estimated that a population-wide surveillance program could potentially result in a total cost of $US289.9 million. The outpatient management of Barrett’s oesophagus is estimated to cost $US1241 per year with medication use alone accounting for over half of the total costs. Cost-effectiveness analyses have been performed to evaluate the economic impact and benefit of surveillance for dysplasia and/or cancer. Studies to date have utilised several outcome measures such as life-years gained, quality-adjusted life-years and cases of cancer detected. Therefore, the incremental cost-effectiveness ratios reported have varied greatly and are particularly sensitive to the prevalence of Barrett’s oesophagus in patients with GORD and the incidence of adenocarcinoma. Further epidemiological and clinical studies are likely to further define the economic impact of Barrett’s oesophagus as a complication of GORD.
Similar content being viewed by others
References
Spechler SJ, Goyal RK. Barrett’s esophagus. N Engl J Med 1986; 315: 362–71
Winters CJ, Spurling TJ, Chobanian SJ, et al. Barrett’s esophagus: a prevalent, occult complication of gastroesophageal reflux disease. Gastroenterology 1987;: 118–24
Spechler SJ. Barrett’s esophagus: what’s new and what to do. Am J Gastroenterol 1989; 84: 220–3
Provenzale D, Schmitt C, Wong JB, et al. Barrett’s esophagus: a new look at surveillance based on emerging estimates of cancer risk. Am J Gastroenterol 1999; 94: 2043–53
Blot WJ, Devesa SS, Kneller RW, et al. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991; 265: 1287–9
Blot WJ, Devesa SS, Fraumeni JF, et al. Continuing climb in rates of esophageal adenocarcinoma: an update [letter]. JAMA 1993; 270: 1320
Lagergren J, Bergstrom R, Lindgren A, et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999; 340: 825–31
Sampliner RE, Practice Parameters Committee of the American College of Gastroenterology. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett’s esophagus. Am J Gastroenterol 1998; 93: 1028–32
Achkar E, Carey W. The cost of surveillance for adenocarcinoma complicating Barrett’s esophagus. Am J Gastroenterol 1988; 83: 291–4
Provenzale D, Kemp JA, Arora S, et al. A guide for surveillance of patients with Barrett’s esophagus. Am J Gastroenterol 1994; 89: 670–80
Falk GW, Ours TM, Richter JE, et al. Practice patterns for surveillance of Barrett’s esophagus in the United States. Gastrointest Endosc 2000; 52: 197–203
Gross CP, Canto MI, Hixson J, et al. Management of Barrett’s esophagus: a national study of practice patterns and their cost implications. Am J Gastroenterol 1999; 94: 3440–7
Cruz-Corea M, Gross CP, Canto MI, et al. The impact of practice guidelines on management of Barrett’s esophagus: a prospective cohort [abstract]. Am J Gastroenterol 2000; 95: 2627
Van Sandick J, Bartelsman JM, van Lanschot JJ, et al. Surveillance of Barrett’s oesophagus: physicians’ practices and review of current guidelines. Eur J Gastroenterol Hepatol 2000; 12: 111–7
Smith AM, Maxwell-Armstrong CA, Welch NT, et al. Surveillance for Barrett’s oesophagus in the UK. Br J Surg 1999; 86: 276–80
Locke GR, Talley NJ, Fett SL, et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997; 112: 1448–56
Levin T, Schmittdiel J, Kunz K, et al. Costs of acid related disorders to a health maintenance organization. Am J Med 1997; 103: 520–8
Eloubeidi MA, Homan RK, Martz MD, et al. A cost analysis of outpatient care for patients with Barrett’s esophagus in a managed care setting. Am J Gastroenterol 1999; 94: 2033–6
Soni A, Sampliner RE, Sonnenberg A, et al. Screening for high-grade dysplasia in gastroesophageal reflux disease: is it cost-effective? Am J Gastroenterol 2000; 95: 2086–93
Heudebert G, Centor R, Marks R, et al. Endoscopy in chronic heartburn to screen for Barrett’s esophagus (BE): can we really afford it? [abstract]. Am J Gastroenterol 1998; 93: 1614
Wright TA, Gray MR, Morris AI, et al. Cost effectiveness of detecting Barrett’s cancer. Gut 1996; 39: 574–9
Streitz JMJ, Ellis FHJ, Tilden RL, et al. Endoscopic surveillance of Barrett’s esophagus: a cost-effectiveness comparison with mammographic surveillance for breast cancer. Am J Gastroenterol 1998; 93: 911–5
Ofman JJ, Lewin K, Ramers C, et al. The economic impact of the diagnosis of dysplasia in Barrett’s esophagus. Am J Gastroenterol 2000; 95: 2946–52
Osgard EM, Hirota WK, Maydonovitch CL, et al. A comparison of screening strategies to diagnose Barrett’s esophagus [abstract]. Gastroenterology 2000; 116: AB: G 1200
Shaheen NJ, Crosby MA, Bozymski EM, et al. Is there publication bias in the reporting of cancer risk in Barrett’s esophagus? Gastroenterology 2000; 119: 333–8
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Arguedas, M.R., Eloubeidi, M.A. Barrett’s Oesophagus. Pharmacoeconomics 19, 1003–1011 (2001). https://doi.org/10.2165/00019053-200119100-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00019053-200119100-00003